All times are listed in CET (Central European Time)
Found 1 Presentation For Request "127P"
127P - Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICI).
- P. Iranzo (Barcelona, Spain)
- P. Iranzo (Barcelona, Spain)
- A. Callejo (Barcelona, Spain)
- D. Marmolejo (Barcelona, Spain)
- J. Assaf (Barcelona, Spain)
- N. Pardo (Barcelona, Spain)
- A. Navarro (Barcelona, Spain)
- A. Martinez-Marti (Barcelona, Spain)
- S. Cedres (Barcelona, Spain)
- N. Diaz Mejia (Barcelona, Spain)
- C. Carbonell (Barcelona, Spain)
- R. Amat (Barcelona, Spain)
- J. Frigola (Barcelona, Spain)
- E. Felip (Barcelona, Spain)
Abstract
Background
Advanced NSCLC treatment has been improved by the emergence of ICI. Only around 20% of unselected patients exhibit a positive response to this type of treatment. Great efforts to identify different factors that can potentially guide clinicians to predict response to ICI are being made. We investigated the role of clinical factors such as PD-L1 expression, age, EGFR mutation(mut) and concomitant medications (statins, oral antidiabetic drugs and betablockers) in a real-world cohort of pts.
Methods
Real life data were obtained from 263 consecutive pts with advanced NSCLC treated with ICI at Vall d'Hebron University Hospital between 2013 and 2019 were studied. Patient data were obtained retrospectively. Progression-free survival (PFS) was calculated using the Kaplan-Meier estimates and cox regression analysis was performed for factors potentially influencing survival.
Results
Median age for pts at diagnosis was 62.3 years (range 33–87). 182 (69.2%) were male; 165 (62.7%) were former smokers and 68 (25.9%) current smokers. Non-squamous was the most common histology (78%). An EGFR mutation was identified in 13 pts (4.94%). At the time of starting treatment with ICI, 86 pts (32.7%) received concomitant statins, 40 (15.2%) oral antidiabetic drugs (OADs) and 35 (13.3%) beta-blockers. Median OS for all pts was 20.8 months (m, CI95% 17.8–25.3) and median PFS was 4.8 m (CI95% 3.7–6.4) for ICI treatment. The median PFS by age group were: 4.9 m in pts younger than 55 years (y); 6.6 m in those with age 55 to 75 y and 5.6 m in older than 75y (p = 0.69, age >75 y vs 55–75 y) (p = 0.96; >75 y vs 55–75 y). Median PFS was 1.8 m for EGFR mut pts and 6.1 m for EGFR wild type (p = 0.02). Median PFS in pts with PD-L1 positive tumours was 11.7 m vs 5.3 m in PD-L1 negative (p = 0.1). Regarding concomitant medications, the results showed that statins, OADs and beta-blockers have no significant effect on PFS. Median PFS for patients receiving statins, OADs and beta-blockers were 7 m (p = 0.49); 8.5 m (p = 0.51) and 3.8 m (p = 0.38) respectively.
Conclusions
These real-world data provide useful information for clinicians helping to identify factors which can be helpful to predict tumour response and potential benefit of ICI therapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Iranzo: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy: F. Hofmann La Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Advisory/Consultancy: Grunenthal. A. Callejo: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: F. Hoffmann La Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer; Advisory/Consultancy: Grunenthal Pharma. J.D. Assaf: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology. N. Pardo: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses: F Hoffmann La Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer. A. Navarro: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses: F Hoffmann La Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Oryzon Genomics. A. Martinez-Marti: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: F. Hoffmann La Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer. S. Cedres: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology; Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Amphera; Advisory/Consultancy, Travel/Accommodation/Expenses: F. Hoffmann La Roche. N.M. Diaz Mejia: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD Oncology. E. Felip: Advisory/Consultancy, Speaker Bureau/Expert testimony: AbbVie; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Blueprint medicines; Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD Oncology; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Advisory/Consultancy, Speaker Bureau/Expert testimony: F. Hoffmann La Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Janssen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck KGaA; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Touchtime; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: Medscape; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Guardant Health; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Research grant/Funding (self), Research grant/Funding (institution): EMD Serono Oncology Innovation. All other authors have declared no conflicts of interest.